Vilazodone — Viibryd — is an SSRI with a built-in 5-HT1A partial agonist. The 5-HT1A partial agonism is the same target buspirone hits, and the theoretical rationale was elegant: by activating 5-HT1A directly, vilazodone might accelerate onset and reduce the SSRI-typical side effects. In practice, the theoretical advantage has not translated into clear clinical superiority over standard SSRIs.
- Class
- Serotonin modulator
- Mechanism
- SERT inhibition + 5-HT1A partial agonism (similar to buspirone's mechanism on 5-HT1A)
- Typical dose
- 10-40 mg/day (titrate over 2 weeks)
- Half-life
- ~25 hours
- FDA indications
- MDD
- Key adverse effects
- Diarrhea (prominent), nausea, headache, sexual dysfunction (somewhat lower than SSRIs)
Black box: Suicidal thinking/behavior in pediatric and young adult patients
Take with food (substantially improves absorption). Less broadly used than other agents — modest differentiation from SSRIs but higher cost.
Two facts dominate vilazodone's bedside character.
First, it must be taken with food. Bioavailability without food drops by roughly fifty percent. The patient who takes vilazodone on an empty stomach is essentially taking half a dose. This isn't a comfort recommendation — it's an efficacy requirement, and it's the single most important thing to communicate at prescription. The patient who doesn't eat breakfast cannot reliably take vilazodone in the morning. The patient who travels and skips meals will have unreliable effect. Counsel this explicitly.
Second, GI side effects — particularly diarrhea — are more prominent than with most SSRIs. The titration is structured over two weeks to mitigate: 10 milligrams for a week, then 20, then up to 40. Some patients adapt; some can't tolerate. The diarrhea is the most common reason vilazodone is discontinued.
Sexual dysfunction rates are somewhat lower than standard SSRIs, attributed to the 5-HT1A partial agonism. The signal is modest — comparable in concept to vortioxetine, less dramatic than bupropion or mirtazapine alternatives.
Vilazodone combines SERT blockade with 5-HT1A partial agonism — a design intended to speed onset and reduce sexual side effects.
Mechanism note: Vilazodone's SERT-plus-5-HT1A design targets faster onset and fewer sexual side effects; GI tolerability and the food requirement are the practical constraints.
Other side effects follow the SSRI pattern: nausea, headache, occasional sleep disturbance, dry mouth. The half-life is about 25 hours, allowing once-daily dosing with reasonably smooth steady-state.
In modern practice, vilazodone is rarely a first choice. It has not produced the breakthrough antidepressant performance the mechanism predicted. The food requirement is a real-world adherence barrier. Cost is meaningful — brand-only for most of its history, though generics now exist. The patient who would benefit specifically from a 5-HT1A partial agonist plus SERT inhibition is uncommon enough that vilazodone occupies a narrow clinical niche.
- Cost
- Generic now ~$30-100/month. Brand Viibryd discontinued for new starts.
- Generic status
- Generic since 2022.
- Formulary typical
- Generic Tier 2-3. Some plans still require PA.
- Access friction
- Food requirement is the daily friction — patient who skips breakfast has subtherapeutic levels.
Prescriber tip: Patient education about food requirement is non-negotiable. Less commonly used now; if patient has done well historically, continue; for new starts, other agents usually fit better.
The general lesson is one about pharmacology design. Combining two targets into one molecule sometimes works — clozapine, aripiprazole, vortioxetine to varying degrees — and sometimes doesn't. Vilazodone is closer to the "doesn't" end. The mechanism reads cleverly; the clinical result is "an SSRI with food requirement and more diarrhea." If the patient has done well on vilazodone historically, leave it alone. For a new start, an SSRI generic is almost always the better choice.